Erica M Sparkenbaugh1, Malgorzata Kasztan2, Michael W Henderson1, Patrick Ellsworth1, Parker Ross Davis2, Kathryn J Wilson1, Brandi Reeves1, Nigel S Key1,3, Sidney Strickland4, Keith McCrae5, David M Pollock2, Rafal Pawlinski1. 1. UNC Blood Research Center, Division of Hematology & Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2. Section of Cardio-Renal Physiology and Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 3. Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. Patricia and John Rosenwald Laboratory of Neurobiology and Genetics, The Rockefeller University, New York, NY, USA. 5. Department of Hematology Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Abstract
BACKGROUND: Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, vaso-occlusive crises, chronic inflammation, and activation of coagulation. The clinical complications such as painful crisis, stroke, pulmonary hypertension, nephropathy and venous thromboembolism lead to cumulative organ damage and premature death. High molecular weight kininogen (HK) is a central cofactor for the kallikrein-kinin and intrinsic coagulation pathways, which contributes to both coagulation and inflammation. OBJECTIVE: We hypothesize that HK contributes to the hypercoagulable and pro-inflammatory state that causes end-organ damage and early mortality in sickle mice. METHODS: We evaluated the role of HK in the Townes mouse model of SCD. RESULTS/ CONCLUSIONS: We found elevated plasma levels of cleaved HK in sickle patients compared to healthy controls, suggesting ongoing HK activation in SCD. We used bone marrow transplantation to generate wild type and sickle cell mice on a HK-deficient background. We found that short-term HK deficiency attenuated thrombin generation and inflammation in sickle mice at steady state, which was independent of bradykinin signaling. Moreover, long-term HK deficiency attenuates kidney injury, reduces chronic inflammation, and ultimately improves survival of sickle mice.
BACKGROUND:Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, vaso-occlusive crises, chronic inflammation, and activation of coagulation. The clinical complications such as painful crisis, stroke, pulmonary hypertension, nephropathy and venous thromboembolism lead to cumulative organ damage and premature death. High molecular weight kininogen (HK) is a central cofactor for the kallikrein-kinin and intrinsic coagulation pathways, which contributes to both coagulation and inflammation. OBJECTIVE: We hypothesize that HK contributes to the hypercoagulable and pro-inflammatory state that causes end-organ damage and early mortality in sickle mice. METHODS: We evaluated the role of HK in the Townes mouse model of SCD. RESULTS/ CONCLUSIONS: We found elevated plasma levels of cleaved HK in sickle patients compared to healthy controls, suggesting ongoing HK activation in SCD. We used bone marrow transplantation to generate wild type and sickle cell mice on a HK-deficient background. We found that short-term HK deficiency attenuated thrombin generation and inflammation in sickle mice at steady state, which was independent of bradykinin signaling. Moreover, long-term HK deficiency attenuates kidney injury, reduces chronic inflammation, and ultimately improves survival of sickle mice.
Authors: M F Whelihan; M Y Lim; M J Mooberry; M G Piegore; A Ilich; A Wogu; J Cai; D M Monroe; K I Ataga; K G Mann; N S Key Journal: J Thromb Haemost Date: 2016-08-31 Impact factor: 5.824
Authors: Masao Kakoki; Kelli A Sullivan; Carey Backus; John M Hayes; Sang Su Oh; Kunjie Hua; Adil M H Gasim; Hirofumi Tomita; Ruriko Grant; Sarah B Nossov; Hyung-Suk Kim; J Charles Jennette; Eva L Feldman; Oliver Smithies Journal: Proc Natl Acad Sci U S A Date: 2010-05-17 Impact factor: 11.205
Authors: Malgorzata Kasztan; Brandon M Fox; Joshua S Speed; Carmen De Miguel; Eman Y Gohar; Tim M Townes; Abdullah Kutlar; Jennifer S Pollock; David M Pollock Journal: J Am Soc Nephrol Date: 2017-03-27 Impact factor: 10.121
Authors: Felicity N E Gavins; Janice Russell; Elena L Senchenkova; Lidiana De Almeida Paula; Amílcar S Damazo; Charles T Esmon; Daniel Kirchhofer; Robert P Hebbel; D Neil Granger Journal: Blood Date: 2011-02-08 Impact factor: 22.113
Authors: Mohammad M Khan; Yuchuan Liu; Munir E Khan; Megan L Gilman; Sabina T Khan; Michael Bromberg; Robert W Colman Journal: Am J Physiol Heart Circ Physiol Date: 2009-12-04 Impact factor: 4.733
Authors: Sergei Merkulov; Wan-Ming Zhang; Anton A Komar; Alvin H Schmaier; Ellen Barnes; Yihua Zhou; Xincheng Lu; Takayuki Iwaki; Francis J Castellino; Guangbin Luo; Keith R McCrae Journal: Blood Date: 2007-11-13 Impact factor: 22.113
Authors: C Emanueli; R Maestri; D Corradi; R Marchione; A Minasi; M G Tozzi; M B Salis; S Straino; M C Capogrossi; G Olivetti; P Madeddu Journal: Circulation Date: 1999-12-07 Impact factor: 29.690